Conor K. Corbin

Conor K. Corbin

Auto-generated profile, based on publicly available information

Conor K. Corbin

SmarterDx, New York, NY, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
QTQandeel Tariq
Qandeel Tariq
SFScott Lanyon Fleming
Scott Lanyon Fleming
JSJessey Nicole Schwartz
Jessey Nicole Schwartz
KDKaitlyn Dunlap
Kaitlyn Dunlap
CCConor Corbin
Conor Corbin
DWDennis Wall
Dennis Wall
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

8 April 2022 in Communications Medicine
Verified
Journal Article
Open access
PDF file
CCConor K. Corbin
Conor K. Corbin
LSLillian Sung
Lillian Sung
ACArhana Chattopadhyay
Arhana Chattopadhyay
MNMorteza Noshad
Morteza Noshad
ACAmy Chang
Amy Chang
JCJonathan H. Chen
Jonathan H. Chen
Background: The Centers for Disease Control and Prevention identify antibiotic prescribing stewardship as the most important action to combat increasing antibiotic resistance. Clinicians balance broad empiric antibiotic coverage vs. precision coverage targeting only the most likely pathogens. We investigate the utility of machine learning-based clinical decision support for antibiotic prescribing stewardship. Methods: In this retrospective multi-site study, we developed machine learning models that predict antibiotic susceptibility patterns (personalized antibiograms) using electronic health record data of 8342 infections from Stanford emergency departments and 15,806 uncomplicated urinary tract infections from Massachusetts General Hospital and Brigham & Women’s Hospital in Boston. We assessed the trade-off between broad-spectrum and precise antibiotic prescribing using linear programming. Results: We find in Stanford data that personalized antibiograms reallocate clinician antibiotic selections with a coverage rate (fraction of infections covered by treatment) of 85.9%; similar to clinician performance (84.3% p = 0.11). In the Boston dataset, the personalized antibiograms coverage rate is 90.4%; a significant improvement over clinicians (88.1% p < 0.0001). Personalized antibiograms achieve similar coverage to the clinician benchmark with narrower antibiotics. With Stanford data, personalized antibiograms maintain clinician coverage rates while narrowing 69% of empiric vancomycin+piperacillin/tazobactam prescriptions to piperacillin/tazobactam. In the Boston dataset, personalized antibiograms maintain clinician coverage rates while narrowing 48% of ciprofloxacin to trimethoprim/sulfamethoxazole. Conclusions: Precision empiric antibiotic prescribing with personalized antibiograms could improve patient safety and antibiotic stewardship by reducing unnecessary use of broad-spectrum antibiotics that breed a growing tide of resistant organisms.

27 June 2023 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
CCConor K Corbin
Conor K Corbin
RMRob Maclay
Rob Maclay
AAAakash Acharya
Aakash Acharya
SMSreedevi Mony
Sreedevi Mony
SPSoumya Punnathanam
Soumya Punnathanam
JCJonathan H Chen
Jonathan H Chen
Objective: Heatlhcare institutions are establishing frameworks to govern and promote the implementation of accurate, actionable, and reliable machine learning models that integrate with clinical workflow. Such governance frameworks require an accompanying technical framework to deploy models in a resource efficient, safe and high-quality manner. Here we present DEPLOYR, a technical framework for enabling real-time deployment and monitoring of researcher-created models into a widely used electronic medical record system. Materials and Methods: We discuss core functionality and design decisions, including mechanisms to trigger inference based on actions within electronic medical record software, modules that collect real-time data to make inferences, mechanisms that close-the-loop by displaying inferences back to end-users within their workflow, monitoring modules that track performance of deployed models over time, silent deployment capabilities, and mechanisms to prospectively evaluate a deployed model’s impact. Results: We demonstrate the use of DEPLOYR by silently deploying and prospectively evaluating 12 machine learning models trained using electronic medical record data that predict laboratory diagnostic results, triggered by clinician button-clicks in Stanford Health Care’s electronic medical record. Discussion: Our study highlights the need and feasibility for such silent deployment, because prospectively measured performance varies from retrospective estimates. When possible, we recommend using prospectively estimated performance measures during silent trials to make final go decisions for model deployment. Conclusion: Machine learning applications in healthcare are extensively researched, but successful translations to the bedside are rare. By describing DEPLOYR, we aim to inform machine learning deployment best practices and help bridge the model implementation gap.

19 August 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
GKGrace Y. E. Kim
Grace Y. E. Kim
MSMatthew Schwede
Matthew Schwede
CCConor K. Corbin
Conor K. Corbin
SFSajjad Fouladvand
Sajjad Fouladvand
RBRondeep Brar
Rondeep Brar
JCJonathan H. Chen
Jonathan H. Chen
Next-generation sequencing-based tests have advanced the field of medical diagnostics, but their novelty and cost can lead to uncertainty in clinical deployment. The Heme-STAMP is one such assay that tracks mutations in genes implicated in hematolymphoid neoplasms. Rather than limiting its clinical usage or imposing rule-based criteria, we propose leveraging machine learning to guide clinical decision-making on whether this test should be ordered. We trained a machine learning model to predict the outcome of Heme-STAMP testing using 3472 orders placed between May 2018 and September 2021 from an academic medical center and demonstrated how to integrate a custom machine learning model into a live clinical environment to obtain real-time model and physician estimates. The model predicted the results of a complex next-generation sequencing test with discriminatory power comparable to expert hematologists (AUC score: 0.77 [0.66, 0.87], 0.78 [0.68, 0.86] respectively) and with the capacity to improve the calibration of human estimates.

23 June 2026 in NEJM AI
Verified
Journal Article
Closed access
ALApril S. Liang
April S. Liang
FAFatemeh Amrollahi
Fatemeh Amrollahi
YJYixing Jiang
Yixing Jiang
CCConor K. Corbin
Conor K. Corbin
GKGrace Y. E. Kim
Grace Y. E. Kim
JCJonathan H. Chen
Jonathan H. Chen
Repetitive laboratory testing that is unlikely to yield clinically useful information is a common practice that burdens patients and increases health care costs. Education and feedback interventions have limited success, while general test ordering restrictions and electronic alerts impede appropriate clinical care. We introduce and evaluate SmartAlert, a machine learning–driven clinical decision support (CDS) system integrated into the electronic health record that predicts stable laboratory results to reduce unnecessary repeat testing. This Case Study describes the implementation process, challenges, and lessons learned from deploying SmartAlert targeting complete blood count (CBC) utilization in a randomized controlled pilot across 9270 admissions in eight acute care units across two hospitals between August 15, 2024, and March 15, 2025. The results show a significant decrease in the number of CBC results within 52 hours of SmartAlert display (1.54 vs. 1.82; P<0.01) without adverse effect on secondary safety outcomes, representing a 15% relative reduction in repetitive testing. Implementation lessons learned include interpretation of probabilistic model predictions in clinical contexts, stakeholder engagement to define acceptable model behavior, governance processes for deploying a complex model in a clinical environment, user interface design considerations, alignment with clinical operational priorities, and the value of qualitative feedback from end users. In conclusion, a machine learning–driven CDS system backed by a deliberate implementation and governance process can provide precision guidance on inpatient laboratory testing to safely reduce unnecessary repetitive testing. (Funded by the Agency for Science, Technology, and Research and others.)

16 September 2022 in arXiv
Verified
Preprint
Open access
PDF file
CCConor K. Corbin
Conor K. Corbin
MBMichael Baiocchi
Michael Baiocchi
JCJonathan H. Chen
Jonathan H. Chen
When evaluating the performance of clinical machine learning models, one must consider the deployment population. When the population of patients with observed labels is only a subset of the deployment population (label selection), standard model performance estimates on the observed population may be misleading. In this study we describe three classes of label selection and simulate five causally distinct scenarios to assess how particular selection mechanisms bias a suite of commonly reported binary machine learning model performance metrics. Simulations reveal that when selection is affected by observed features, naive estimates of model discrimination may be misleading. When selection is affected by labels, naive estimates of calibration fail to reflect reality. We borrow traditional weighting estimators from causal inference literature and find that when selection probabilities are properly specified, they recover full population estimates. We then tackle the real-world task of monitoring the performance of deployed machine learning models whose interactions with clinicians feed-back and affect the selection mechanism of the labels. We train three machine learning models to flag low-yield laboratory diagnostics, and simulate their intended consequence of reducing wasteful laboratory utilization. We find that naive estimates of AUROC on the observed population undershoot actual performance by up to 20%. Such a disparity could be large enough to lead to the wrongful termination of a successful clinical decision support tool. We propose an altered deployment procedure, one that combines injected randomization with traditional weighted estimates, and find it recovers true model performance.